Cellyan Biotechnology Receives Nasdaq Compliance Grace Period
Cellyan Biotechnology, engaged in cross-border e-commerce supply chain services, received an additional 180-day grace period from Nasdaq to meet minimum stock price compliance requirements. The company will implement various measures to maintain its listing status.
What are the key facts?
- 1Granted 180-day additional compliance grace period by Nasdaq
- 2Must meet minimum closing price requirement of $1
- 3Deadline is January 11, 2027
What happened?
Cellyan Biotechnology received a notice from Nasdaq granting it an additional 180-day grace period (until January 11, 2027) to meet the minimum closing price of $1 required for listing. The company stated it would take necessary measures, including possibly executing a reverse stock split, to regain compliance and protect shareholder interests.
What does this mean for cross-border sellers?
As a cross-border supply chain service provider, its capital market stability affects business sustainability; collaborating sellers should pay attention to its financial status.